Serum cyclosporine kinetic profile. Failure to correlate with nephrotoxicity or rejection episodes following sequential immunotherapy for renal transplantation.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-198801000-00020PMID 3276069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tailoring cyclosporine according to kinetic profiles: does it allow a low-dose therapeutic schedule?

  1987cited by this paper
• SEQUENTIAL ANTILYMPHOBLAST GLOBULIN AND CYCLOSPORINE FOR RENAL TRANSPLANTATION

  1987cited by this paper
• Cyclosporine pharmacokinetics in the early course of renal transplantation.

  1987cited by this paper
• Optimal use of cyclosporine in clinical organ transplantation.

  1987cited by this paper
• DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY

  1986cited by this paper
• Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation.

  1986cited by this paper
• Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection.

  1985cited by this paper
• Mismatched living, related donor renal transplantation: a prospective, randomized study.

  1985cited by this paper
• Cyclosporin in renal transplantation: a guide to management.

  1984cited by this paper
• Cyclosporine: five years' experience in cadaveric renal transplantation.

  1984cited by this paper
• Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone.

  1983cited by this paper
• IMMUNOPHARMACOLOGICAL MONITORING OF CYCLOSPORIN A‐TREATED RECIPIENTS OF CADAVERIC KIDNEY ALLOGRAFTS

  1982cited by this paper
• Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

  1981cited by this paper

• Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis

  2020cites this paper
• Therapeutic monitoring of cyclosporin — an update

  2004cites this paper
• Toxic effects of imm U flO 5 U ppressive drugs : mechanisms and strategies for controlling them

  2004cites this paper
• Evolution of the therapeutic drug monitoring of cyclosporine.

  2004cites this paper
• Methods for Clinical Monitoring of Cyclosporin in Transplant Patients

  2000cites this paper
• Impact of early cyclosporin average blood concentration on early kidney transplant failure

  1998cites this paper
• Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts.

  1997cites this paper
• The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy

  1996cites this paper
• Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients

  1996cites this paper
• Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them.

  1996cites this paper
• Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs.

  1993cites this paper
• THE ADVERSE IMPACT OF HIGH CYCLOSPORINE: CLEARANCE RATES ON THE INCIDENCES OF ACUTE REJECTION AND GRAFT LOSS

  1993cites this paper
• Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation

  1993cites this paper
• Toward a Rational Design of Clinical Trials of Immunosuppressive Agents in Transplantation

  1993cites this paper
• Evidence that sensitivity to cyclosporine is influenced by the HLA-DR phenotype of kidney graft recipients.

  1992cites this paper
• Pharmacokinetic strategies for cyclosporin therapy in organ transplantation.

  1992cites this paper
• Analyzing the number of "rejection episodes" in renal transplant studies.

  1992cites this paper
• Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window.

  1991cites this paper
• Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients.

  1990cites this paper
• Current status of renal transplantation.

  1990cites this paper
• Influence of HLA phenotypes on the inhibition of in vitro alloreactivity by cyclosporine.

  1990cites this paper
• Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility.

  1990cites this paper
• Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel.

  1990cites this paper
• Monitoring of cyclosporine by serial posttransplant pharmacokinetic studies in renal transplant patients.

  1990cites this paper
• Principles of immunosuppression.

  1990cites this paper
• Immunohistological analysis of renal allograft biopsies from cyclosporin‐treated patients: Induced HLA‐class II antigen expression does not exclude a diagnosis of cyclosporin nephrotoxicity

  1989cites this paper
• Cyclosporine blood level and early transplant function of cadaver donor kidneys.

  1989cites this paper
• Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis.

  1989cites this paper
• Immunohistological analysis of renal allograft biopsies from cyclosporin-treated patients

  1989cites this paper
• The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients.

  1988cites this paper